Navigation Links
Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy
Date:3/20/2009

nts receiving moderately emetogenic chemotherapies. A single intravenous dose of palonosetron (0.25 mg) provides better protection from CINV than first-generation 5-HT3 receptor antagonists throughout a 5-day post-chemotherapy period*. This means that a single administration of palonosetron also grants protection during the delayed phase of CINV*.

Palonosetron 0.075 mg IV is also approved by FDA as a single intravenous dose administered immediately before the induction of anaesthesia for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

Palonosetron is contraindicated in patients known to have hypersensitivity to the drug or any of its components. The most commonly reported adverse reactions (incidence greater than or equal to 2%) in CINV trials with palonosetron were headache (9%) and constipation (5%), and they were similar to the comparators. In PONV trials, the most commonly reported adverse reactions were QT prolongation (5%), bradycardia (4%), headache (3%), and constipation (2%), similar to placebo.

Palonosetron has been developed by Helsinn Healthcare SA of Switzerland and today it is marketed as Aloxi(R), Onicit(R), and Paloxi(R). Palonosetron, marketed as Aloxi(r), is the leading brand in the USA within the CINV Day of Chemo segment, and it is steadily growing in the European markets. Its approval in Japan is expected during 2009.

For more information about palonosetron, please visit the website: http://www.aloxi.com

About Helsinn Group

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and subsidiaries in Ireland and USA. Helsinn is the worldwide licensor of palonosetron.

Helsinn's unique business model is focused on the licensing of pharmaceuticals and medical devices in therapeutic niche areas. The Gr
'/>"/>

SOURCE Helsinn Healthcare SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
2. Imagenetix Reports Results of Offer to Extend Warrants
3. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
4. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
6. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
7. China Bio Energy Holdings Group Announces Financing and Exercise of Warrants
8. Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS
9. Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology
10. Results of Study in Pre-School Children Published in Clinical Pediatrics Adds to Support for Importance of Dietary DHA Intake
11. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Portage Biotech Inc. ("Portage" or "the Company" )) (OTC ... announce that the Company will be presenting  at the ... held in London, UK . Portage,s ... James Mellon , a director of Portage, will provide ... at its subsidiaries, Portage Pharmaceuticals Ltd. ("PPL"), and Biohaven ...
(Date:4/16/2015)... 2015 ChemRar High ... and R&D group, and Lancet, Russian Distribution ... and commercialization of new medicines in ... to stimulate the innovative development of the ... http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... , April 16, 2015  Scientists from Cleave ... Drugs on the Horizon," at the American Association for ... PA on Sunday, April 19, 2015 from ... Cleave,s Director of Biology, will present new in vivo ... first-in-class, oral inhibitor of p97, a critical enzyme that ...
(Date:4/16/2015)... , Switzerland , ... Debiopharm International SA (Debiopharm), part of Debiopharm Group ™ , ... drugs that target unmet medical needs as ... preclinical data on the investigational compounds Debio 1143 ... will be presented at the 2015 Annual ...
Breaking Biology Technology:Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
... July 25, 2011 MiMedx Group, Inc.  (OTCBB: MDXG), ... regenerative biomaterials and bioimplants processed from human amniotic membrane, ... six months ended June 30, 2011. The ... an 85% percent increase over first quarter of 2011 ...
... ERT (NASDAQ: ERT ) announced today that it ... Monday, August 1, after the market closes.  After the release, ... ET that day. For the conference call, ... States or 1-412-858-4600 when calling internationally. There will be a ...
... SHELTON, Conn., July 22, 2011 Modern Plastics, one ... stock shapes and medical-grade plastics, has moved from ... new address is 88 Long Hill Cross Road, Shelton, ... features an advanced environmentally controlled clean room for storage ...
Cached Biology Technology:MiMedx Group Announces Second Quarter 2011 Results 2MiMedx Group Announces Second Quarter 2011 Results 3MiMedx Group Announces Second Quarter 2011 Results 4MiMedx Group Announces Second Quarter 2011 Results 5MiMedx Group Announces Second Quarter 2011 Results 6MiMedx Group Announces Second Quarter 2011 Results 7MiMedx Group Announces Second Quarter 2011 Results 8MiMedx Group Announces Second Quarter 2011 Results 9MiMedx Group Announces Second Quarter 2011 Results 10ERT Reports Second Quarter 2011 Operating Results on August 1, 2011 2
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
(Date:4/1/2015)... 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces the second ... is underway to early access pre-order customers. ... at retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, ... was accepted at all outlets and very easy to ...
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... bioMETRX Inc., (OTC,Bulletin Board: BMRX), today announced ... agreement with EZ Print, LLC for the advanced ... purchase,agreement., EZ Print, LLC will invest considerable ... the enterprise document production,business. Currently the technology branded ...
... largest field trial of its kind in the United ... Miscanthus x giganteus outperforms current biofuels sources by ... production in the U.S. could significantly reduce the acreage ... the researchers report. The new findings, from researchers ...
... (CLIC), a group of researchers from 10 academic and ... by physicians at Case Western Reserve University School of ... grant from the National Institutes of Health (NIH) to ... deficiency that causes AIDS. The grant will fund four ...
Cached Biology News:bioMETRX, Inc. Completes Exclusive Licensing Agreement With EZ Print, LLC 2bioMETRX, Inc. Completes Exclusive Licensing Agreement With EZ Print, LLC 3Miscanthus can meet US biofuels goal using less land than corn or switchgrass 2Miscanthus can meet US biofuels goal using less land than corn or switchgrass 3Case Western Reserve University School of Medicine researchers receive $10.8 million 2
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
Request Info...
Imject Freund's Complete Adjuvant (FCA)...
... the secretion of cytoplasmic granules, is ... response of leukocytes (e.g. basophils, neutrophils, ... to histamine, these secretory granules contain ... chemokines, and many proteases (Hallgren, 2001). ...
Biology Products: